Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 26/10/2016 genewerk-cmyk.jpg

    GeneWerk: precision analyses for humans

    Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genewerk-precision-analyses-for-humans
  • High-tech - 20/10/2016 Man standing in front of a robot.

    Industry 4.0 in the medical technology and pharmaceutical industry sectors

    The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
  • European Health Science Match in Heidelberg
 - 19/10/2016 Four men in suits listening to a speech.

    100 exciting health research projects

    Around 600 people came to the ”European Health Science Match” conference in Heidelberg to listen to 100 leading up-and-coming researchers from all over Europe, each of whom had three minutes to present their current research projects on the diagnosis and therapy of disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-health-science-match-in-heidelberg-100-exciting-health-research-projects
  • Article - 10/10/2016 Teva Biotech production plant.

    Teva plans the large-scale production of monoclonal antibodies in Ulm

    Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.

    https://www.gesundheitsindustrie-bw.de/en/article/news/teva-plans-the-large-scale-production-of-monoclonal-antibodies-in-ulm
  • Article - 04/10/2016 Photo of Dr. Benjamin Streb (right) and Elli Mohr (lef) from the Springer publishing house supervise students during a four-year course leading to a Bachelor of Science degree in molecular biology.

    Distance learning course in molecular biology – from lab to studies

    In cooperation with the University of Mainz, the Springer publishing house is now offering distance learning courses for laboratory and technical assistants who wish to study while they are working. The courses lead to a Bachelor of Science degree. The successful programme for ambitious non-academics is being developed in several Baden-Württemberg cities.

    https://www.gesundheitsindustrie-bw.de/en/article/news/distance-learning-course-in-molecular-biology-from-lab-to-studies
  • Business location Baden-Württemberg - 29/09/2016 Gruppenbild_Parlamentarisches_Fruhstuck.jpg

    "Well done - biotechnology as the driver of innovations in Baden-Württemberg"

    Eight members of the Bundestag from Baden-Württemberg attended the Parliamentary Breakfast on 21st September 2016 in Berlin where information was presented on the performance of the biotechnology sector in Baden-Württemberg. The politicians also discussed with entrepreneurs ways of improving general conditions in the sector.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/clever-gemacht-biotechnologie-als-innovationsmotor-in-baden-wuerttemberg
  • Article - 26/09/2016 Proteinkinasen.jpg

    TuCADD: Coaching for early drug candidates

    The University of Tübingen is optimising its drug development pipeline. The TuCADD consortium provides professional help to people who want to take potential drug candidates to clinical application. The coaching involves assistance with the entire phase I drug development phase from industry experts.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tucadd-coaching-for-early-drug-candidates
  • Article - 20/09/2016 Prof. Dr. Anita Marchfelder, spokesperson and coordinator of the DFG research group FOR1680.

    CRISPR-Cas has more surprises in store

    Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
  • Article - 13/09/2016 Production of white tablets.

    Catalent – galenics experts from Schorndorf

    Pharmaceutical and biotechnology companies are working intensively on the discovery and development of new drugs for the efficient and safe treatment of diseases. However, before drugs are authorised for treating humans and animals, they have to be made into a form that is acceptable. That is where a company called Catalent Pharma Solutions, with a facility in Schorndorf in the south of Germany, comes in.

    https://www.gesundheitsindustrie-bw.de/en/article/news/catalent-galenics-experts-from-schorndorf
  • Article - 12/09/2016 Photo of the building housing the Department of Internal Medicine in Tübingen.

    New target for the therapy of hepatocellular carcinoma discovered

    Hepatocellular carcinoma is the second most common cause of cancer deaths worldwide. If the tumour is at an advanced stage, doctors have few treatment options. Researchers led by Prof. Dr. Lars Zender from the University of Tübingen have now identified one of the cancer's Achilles' heels, namely, the interaction between C-MYC and AURKA proteins, which can be destabilised with a drug, thus killing cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-target-for-the-therapy-of-hepatocellular-carcinoma-discovered
  • Article - 08/09/2016 Computer image of gold molecules to which a diamondoid and a DNA molecule are bound.

    A diamond might make sequencing more accurate

    DNA sequencing techniques have been developed along the lines of faster, further, cheaper. State-of-the-art methods make it possible to handle large projects in a relatively short period of time. However, the error rate is still very high. Dr. Maria Fyta and her team at the Institute for Computational Physics at the University of Stuttgart have carried out quantum-transport calculations which suggested that specific chemical modifications in the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-diamond-might-make-sequencing-more-accurate
  • Article - 05/09/2016 Glioblastom_MRT.jpg

    Apogenix: immuno-oncological protein drugs for the treatment of malignant diseases

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-immunonkologische-proteinwirkstoffe-gegen-maligne-erkrankungen
  • Article - 01/09/2016 Woman holding a small round piece of fabric.

    Tailor-made biotech fibres for improved wound dressings

    Scientists have developed a biotechnological process to produce bacterial alginate. The alginate quality is highly reproducible, making it suitable for the production of fibre-based medicinal products such as wound dressings.

    https://www.gesundheitsindustrie-bw.de/en/article/news/made-to-measure-biotech-fibres
  • Article - 29/08/2016 B/w microscope image of pancreas organoids of different sizes. They are round and hollow.

    Cellendes and EU partners develop cell therapy for treating type 1 diabetes

    Cells derived from suitable donor stem cells that can do the work defective insulin-producing cells can no longer do are the central focus of a European cell therapy project involving Reutlingen-based Cellendes GmbH as one of the partners. Cellendes develops a biomaterial that facilitates the mass production of cells and could potentially be approved for therapeutic use in humans.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cellendes-und-eu-partner-entwickeln-zelltherapie-fuer-diabetes-typ-1
  • Article - 22/08/2016 Schematic of a modified virus.

    Ad-O-Lytics – a new biotech start-up from Ulm

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ad-o-lytics-a-new-biotech-start-up-from-ulm
  • Article - 18/08/2016 Schematic showing the excretion of toxic proteins. Specifically, the schematic shows a bacterial cell and a human cell (circles) and toxic products (small dots) that dock to cells.

    Moonlighting proteins can make bacteria pathogenic

    The mechanism underlying the export of biomolecules from cells remains unknown. Prof. Dr. Friedrich Götz and his team at the Institute of Microbial Genetics at the University of Tübingen have found out that staphylococci can turn into dangerous pathogens by excreting normally harmless enzymes. The researchers believe that the enigmatic excretion of such enzymes is due to a completely new mechanism and are thus planning to carry out further…

    https://www.gesundheitsindustrie-bw.de/en/article/news/moonlighting-proteins-can-make-bacteria-pathogenic
  • Article - 18/08/2016 HCV_particles_EM.jpg

    Chronic viral infections of the liver

    Hepatitis B and hepatitis C are two of the most common infectious diseases in the world. They often take a chronic course and carry a high risk of progressing to cirrhosis and hepatocellular carcinoma. A new transregional collaborative research centre involving scientists from Heidelberg and Freiburg is looking into how hepatitis B and hepatitis C viruses, which have different symptoms and treatments, are able to evade the immune system and allow…

    https://www.gesundheitsindustrie-bw.de/en/article/news/chronic-viral-infections-of-the-liver
  • Article - 08/08/2016 Schematic cut through an eye into which the gene therapy is injected.

    First achromatopsia gene therapy clinical trial in Germany is going well

    Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…

    https://www.gesundheitsindustrie-bw.de/en/article/news/first-achromatopsia-gene-therapy-clinical-trial-in-germany-is-going-well
  • Article - 02/08/2016 Huntington_Eiweiss_Abb_Dr_Katrin_Lindenberg_Neurologie_UK_Ulm.jpg

    Can the ticking Huntington clock be stopped?

    An early phase clinical study involving thirty-six Huntington’s disease (HD) patients is currently underway to investigate whether a method called gene silencing can cure the disease. If the gene that causes the disease can be turned off, it would be the first step towards a treatment that not only fights symptoms but actually treats the causes of HD, hence providing a cure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/can-the-ticking-huntington-clock-be-stopped
  • Article - 27/07/2016 The left part of the schematic shows the phylogenetic tree of Ebola viruses. The different regions where the Ebola viruses were found are represented in different colours. The right side shows a map of West Africa; the regions where the viruses used for the analysis were found have the same colour as the respective lines in the tree.

    “Open science“ – a successful recipe for combating viruses

    Danger identified, danger averted – the better the dynamic changes of the viral genome are understood, the better the spread of the pathogens can be predicted, thus enabling more efficient countermeasures to be taken. A team of researchers from Tübingen and Seattle is developing an open source online platform that maps the evolution of viruses and identifies dangerous developments.

    https://www.gesundheitsindustrie-bw.de/en/article/news/open-science-a-successful-recipe-for-combating-viruses
  • Company profile - 25/07/2016 300microns-3D-Zellaggregate.jpg

    300MICRONS: 3D cell culture solutions tailored to customer needs

    What happens in tissues and organs and how do they react to pharmaceutical substances? Three-dimensional cell cultures can reproduce reality far better than a single-cell layer can. With good reason. Reality is far from two-dimensional. A company called 300MICRONS GmbH develops films with tiny indentations that provide optimal conditions for cells to grow into 3D cell aggregates.

    https://www.gesundheitsindustrie-bw.de/en/article/news/300microns-3d-cell-culture-solutions-tailored-to-customer-needs
  • Article - 21/07/2016 Photo of three hop cones.

    New anticancer drugs – hop compounds have the potential to treat cancer

    Secondary hop compounds appear to have a positive effect on the immune system and therefore have the potential to be used for the treatment and prevention of cancer. However, the bioavailability of hop compounds in the human body is relatively poor. Researchers from Hohenheim and Tübingen are therefore looking for a way to increase their absorption rate.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-drugs-for-the-treatment-of-cancer-hop-compounds-have-the-potential-to-treat-cancer
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
  • Company profile - 18/07/2016 A tablet computer and a smartphone with a medical image.

    mbits imaging GmbH – mobile app in the field of radiology

    Trying to get a second opinion from a medical colleague who is at home preparing dinner may be quite a challenge, especially when the colleague does not have access to the necessary image data. This has now become easier in the field of radiology thanks to a mobile app called mRay, which provides a reliable way for radiologists to share medical images on mobile devices.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mbits-imaging-gmbh-mobile-app-in-the-field-of-radiology
  • Company profile - 14/07/2016 Schematic showing how the neurostimulator leads to the stimulation of the vagus nerve lowers the blood pressure.

    neuroloop GmbH: how the manipulation of neuronal information can lower blood pressure

    Millions of people worldwide suffer from high blood pressure. However, taking medicines to control high blood pressure does not work for everyone. Dr. Dennis Plachta and Prof. Dr. Thomas Stieglitz from IMTEK have now developed a neurostimulator to control blood pressure. Together with Dr. Michael Lauk, an experienced company founder, the two researchers set up a company called neuroloop, which is funded by Aesculap AG and aims to turn the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/neuroloop-gmbh-how-the-manipulation-of-neuronal-information-can-lower-blood-pressure

Page 25 / 120

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 120
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search